drugset / Trial / NCT03720431
TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer
NaSequentialOpen-labelTreatment
Summary
This is a phase 1b, open-Label clinical trial to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of TTAC-0001 administered in combination with pembrolizumab in patients with metastatic triple-negative breast cancer.
Timeline
- Start
- 2019-01-03
- Primary completion
- 2020-03-18
- Completion
- 2022-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olinvacimab | Monoclonal antibody | 8 mg/kg | — |
| Subject | Olinvacimab | Monoclonal antibody | 12 mg/kg | — |
| Subject | Olinvacimab | Monoclonal antibody | 16 mg/kg | — |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | — |